These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

937 related articles for article (PubMed ID: 31106425)

  • 1. Epithelial-mesenchymal transition in the formation of hypertrophic scars and keloids.
    Yuan FL; Sun ZL; Feng Y; Liu SY; Du Y; Yu S; Yang ML; Lv GZ
    J Cell Physiol; 2019 Dec; 234(12):21662-21669. PubMed ID: 31106425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hyperplastic scars and keloids. Part I: basics and prevention].
    Baisch A; Riedel F
    HNO; 2006 Nov; 54(11):893-904; quiz 905. PubMed ID: 17041777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelial dysfunction may play a key role in keloid and hypertrophic scar pathogenesis - Keloids and hypertrophic scars may be vascular disorders.
    Ogawa R; Akaishi S
    Med Hypotheses; 2016 Nov; 96():51-60. PubMed ID: 27959277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypertrophic and keloid scars fail to progress from the CD34
    Limandjaja GC; Belien JM; Scheper RJ; Niessen FB; Gibbs S
    Br J Dermatol; 2020 Apr; 182(4):974-986. PubMed ID: 31206605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Keloids and hypertrophic scars: are they two different sides of the same coin?
    Köse O; Waseem A
    Dermatol Surg; 2008 Mar; 34(3):336-46. PubMed ID: 18177398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Research advances on the role and mechanism of inflammatory response in the formation of hypertrophic scars and keloids].
    Wang HT; Han JT; Hu DH
    Zhonghua Shao Shang Za Zhi; 2021 May; 37(5):490-494. PubMed ID: 34044530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies.
    Gauglitz GG; Korting HC; Pavicic T; Ruzicka T; Jeschke MG
    Mol Med; 2011; 17(1-2):113-25. PubMed ID: 20927486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies of transforming growth factors beta 1-3 and their receptors I and II in fibroblast of keloids and hypertrophic scars.
    Bock O; Yu H; Zitron S; Bayat A; Ferguson MW; Mrowietz U
    Acta Derm Venereol; 2005; 85(3):216-20. PubMed ID: 16040405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Keloids are transcriptionally distinct from normal and hypertrophic scars.
    Walter AS; Stocks M; Akova E; Gauglitz G; Hartmann D; Aszodi A; Böcker W; Saller MM; Volkmer E
    Eur J Dermatol; 2023 Dec; 33(6):604-611. PubMed ID: 38465540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypertrophic scars and keloids.
    Haverstock BD
    Clin Podiatr Med Surg; 2001 Jan; 18(1):147-59. PubMed ID: 11344975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow derived mesenchymal stem cells inhibit the proliferative and profibrotic phenotype of hypertrophic scar fibroblasts and keloid fibroblasts through paracrine signaling.
    Fang F; Huang RL; Zheng Y; Liu M; Huo R
    J Dermatol Sci; 2016 Aug; 83(2):95-105. PubMed ID: 27211019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Keloids: current concepts of pathogenesis (review).
    Bran GM; Goessler UR; Hormann K; Riedel F; Sadick H
    Int J Mol Med; 2009 Sep; 24(3):283-93. PubMed ID: 19639219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Understandings of Biology, Prophylaxis and Treatment Strategies for Hypertrophic Scars and Keloids.
    Lee HJ; Jang YJ
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29498630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in scar management: prevention and management of hypertrophic scars and keloids.
    Del Toro D; Dedhia R; Tollefson TT
    Curr Opin Otolaryngol Head Neck Surg; 2016 Aug; 24(4):322-9. PubMed ID: 27163611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical Evaluation of Leptin Expression in Wound Healing: A Clue to Exuberant Scar Formation.
    Seleit I; Bakry OA; Samaka RM; Tawfik AS
    Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):296-306. PubMed ID: 26258753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypertrophic scars and keloids: Overview of the evidence and practical guide for differentiating between these abnormal scars.
    Limandjaja GC; Niessen FB; Scheper RJ; Gibbs S
    Exp Dermatol; 2021 Jan; 30(1):146-161. PubMed ID: 32479693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of the anti-allergic agent avil on abnormal scar fibroblasts.
    Venugopal J; Ramakrishnan M; Habibullah CM; Babu M
    Burns; 1999 May; 25(3):223-8. PubMed ID: 10323606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascularization pattern in hypertrophic scars and keloids: a stereological analysis.
    Amadeu T; Braune A; Mandarim-de-Lacerda C; Porto LC; Desmoulière A; Costa A
    Pathol Res Pract; 2003; 199(7):469-73. PubMed ID: 14521263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of apoptosis in keloids and a comparative study on apoptosis between keloids, hypertrophic scars, normal healed flat scars, and dermatofibroma.
    Akasaka Y; Fujita K; Ishikawa Y; Asuwa N; Inuzuka K; Ishihara M; Ito M; Masuda T; Akishima Y; Zhang L; Ito K; Ishii T
    Wound Repair Regen; 2001; 9(6):501-6. PubMed ID: 11896992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrillin-1 and elastin are differentially expressed in hypertrophic scars and keloids.
    Amadeu TP; Braune AS; Porto LC; Desmoulière A; Costa AM
    Wound Repair Regen; 2004; 12(2):169-74. PubMed ID: 15086768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.